Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis
John Mascarenhas(Tisch Hospital), Ronald Hoffman(Icahn School of Medicine at Mount Sinai), Lonette Sandy(Icahn School of Medicine at Mount Sinai), Craig M. Kessler(Georgetown University), Heidi Kosiorek(Mayo Clinic in Florida), Maria R. Baer(University of Maryland, Baltimore), Rona Singer Weinberg(University of North Carolina at Chapel Hill), Leah Price(Cwm Taf University Health Board), Amylou C. Dueck(Mayo Clinic in Arizona), Elizabeth O. Hexner(University of Pennsylvania), Lewis R. Silverman(Icahn School of Medicine at Mount Sinai), Judith D. Goldberg(New York University), Douglas Tremblay(Tisch Cancer Institute), Heike L. Pahl(University Medical Center Freiburg)
Cited by 19
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k